Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Antiviral Res. 2019 May 31;168:134–145. doi: 10.1016/j.antiviral.2019.05.015

Figure 8. ONC201 pretreatment increases its efficacies against HIV-1 infection in macrophages.

Figure 8.

Human MDM were plated in 96-well plates and incubated with doses of ONC201 or its isomer ranging from 3 to 30 μM for 5 days before infection with HIV-1. ONC201 and isomer treatments continued during and after the infection. A) At three-day post infection, cell viability was determined by the MTS assays. B) Cell lysates were collected and subsequently subjected to SDS-PAGE and immunoblotting for the detection of cleaved caspase-3 and pro-caspase-3. Actin was used as the loading control. C) Densitometric quantifications of cleaved caspase-3 in MDM were presented as a ratio to pro-caspase-3 and normalized as fold changes to the vehicle control DMSO group. D) Supernatants were collected and the replication levels of HIV-1 were monitored by RTase activity assay. Results shown are from representative experiments performed with three different donors. Data were analyzed by two-way ANOVA: * denotes p < 0.05, ** denotes p < 0.01, *** denotes p < 0.001, compared to the vehicle control DMSO group.